TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Documented HIV infection~* Subjects must have taken HAART 6 months prior to study entry and must be on stable HAART (no dose change to antiretroviral medications) for at least 30 days immediately prior to study entry~* HDL \< 40 mg/dL • LDL \< 130 mg/dL~* All subjects with reproductive potential should utilize adequate contraception for the duration of this study and for at least 12 weeks following permanent discontinuation of study treatment. Acceptable methods include male condom, female condom, diaphragm, or intra-uterine device (IUD)~Exclusion Criteria:~* Known cardiac disease~* Arrhythmia~* History of angina~* Uncontrolled hypertension~* Pregnancy~* Breast-feeding~* Medication known to influence vasodilatation such as nitrates, metformin, pioglitazone, and rosiglitazone~* Heavy use of vitamin supplements~* Diagnosis of diabetes mellitus~* Treatment with lipid-lowering drugs within 6 weeks prior to study~* Hemoglobin \<9.0 mg/dL~* Absolute neutrophil count \<750 cells/mm3~* Platelet count \<75,000 platelets/ mm3~* Alanine aminotransferase (ALT or SGOT)/ aspartate aminotransferase (AST or SGPT) / alkaline phosphatase \> 2.5 x upper limit of normal (ULN)~* Creatinine \>1.5 x ULN~* Individuals with an infection or other medical illness requiring hospitalization within 14 days prior to study entry~* Individuals who have active alcohol or drug abuse which, in the investigator's opinion, is sufficient to prevent adequate compliance with study therapy and evaluations~* Prior history of hypersensitivity reaction to niacin or any other component of the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active Drug (extended release niacin) (Type: EXPERIMENTAL): Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
- Observation (Type: NO_INTERVENTION): Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of High Flow Nasal Cannula and Standard Face Mask Oxygen Therapy in Children With Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 1-24 months applied with moderate and severe bronchiolitis requiring supplemental oxygen were eligible for the study.~* The severity of bronchiolitis was assessed according to the clinical respiratory score (CRS) of Liu et al. (5). The patients with CRS ≥5 were included.~* Peripheral oxyhemoglobin saturation is \< 92%.~Exclusion criteria:~* Children admitted to the ICU for urgent invasive mechanical ventilation;~* those who received standard oxygen therapy (SOT) or HFNCOT at other facilities before arrival;~* those with an underlying medical condition (such as congenital heart disease, chronic lung disease, neuromuscular disease, metabolic disease, or immunocompromised);~* those who had a craniofacial malformation, an upper airway obstruction, pneumothorax, or nasal trauma, and missing parental consent or a refused permission of the participant.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Active Comparator: HFNCOT (Type: ACTIVE_COMPARATOR): Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation \>92%.
- Active Comparator: St-FMOT (Type: ACTIVE_COMPARATOR): To obtain oxygen saturation \>92%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and/or cytologically confirmed breast cancer~* Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen~* To have at least one measurable region~* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1~* To have adequate organ function (bone marrow, liver and renal function)~Exclusion Criteria:~* To have interstitial pneumonia or pulmonary fibrosis~* To have inflammatory breast cancer~* Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery~* To have brain metastases with symptoms~* To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Diagnosis of sepsis or septic shock within 12 hours of admission to the ICU ii. Informed consent as dictated by IRB and local practice. iii. Compliance with the 3 hour sepsis bundle~* 30ml/kg of intravenous crystalloid fluid (e.g.: sodium chloride 0.9%) for lactic acid \>4 and/or systolic blood pressure \<90mmHg / mean arterial pressure \<65mmHg~* Lactic acid level drawn~* Broad spectrum antibiotics given after obtaining blood cultures~Exclusion Criteria:~i. Age \< 18 years ii. Pregnant iii. DNR/DNI with limitations of care on admission iv. Patients with terminal end stage disease (i.e. stage IV cancer, end stage heart failure) that are unlikely to survive to hospital discharge v. Patients with a primary admitting diagnosis of an acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma \[64-66\] vi. Requirement for immediate surgery \[64-66\] vii. Patients with HIV and a CD4 \< 50 mm2 \[64-66\] viii. Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.\[39\] ix. Patients with sepsis/septic shock transferred from another hospital x. Patients with features of sepsis/septic shock \> 24 hours after admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being diagnosed as IBS according to the Rome III criteria;~* Diarrhea was present for at least 75% of the time;~* With a TCM differentiation as liver stagnation and spleen defficiency~* Had a colonoscopy within a year to rule out other bowel diseases.~Exclusion Criteria:~* Organic gastrointestinal disease, such as colorectal cancer, inflammatory bowel disease, advanced colonic polyp;~* Had gastrointestinal surgery within a year;~* Used durgs that affect gastrointestinal motility;~* Had psychological disorder;~* Serious disease in other system, which may bias the outcome measures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tong-Xie-Yao-Fang (Type: EXPERIMENTAL): Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sufficient understanding of the German language~* Subjects understand the procedures and the risks associated with the study~* Participants must be willing to adhere to the protocol and sign the consent form~* Participants must be willing to refrain from taking illicit psychoactive substances during the study.~* Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session. Subjects must agree not to smoke tobacco for 1 h before and 4 hours after MDMA administration.~* Participants must be willing not to drive a traffic vehicle in the evening of the study day.~* Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.~* Body mass index: 18-25 kg/m2~Exclusion Criteria:~* Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.~* Current or previous psychotic or affective disorder~* Psychotic or affective disorder in first-degree relatives~* Prior illicit drug use (except THC (Tetrahydrocannabinol)-containing products) more than 5 times or any time within the previous 2 months.~* Pregnant or nursing women.~* Participation in another clinical trial (currently or within the last 30 days)~* Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- duloxetine, MDMA, placebo (Type: OTHER): Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 40~* Ability to provide consent~* COPD diagnosis~* Forced Expiratory Volume in one second (FEV1) \<55 and ≥ 25 percent of predicted value~* Perceived Shortness of Breath via the Modified Medical Research Counsel Dyspnea questionnaire (rating of 2 or greater) (Appendix B)~* Able to follow directions~* Able to tolerate mild physical activity~* Pursed Lip Breathing as standard of care~* No evidence of bullous lung disease (with any bullae greater than 3cm in diameter) as confirmed by a CT scan within the past one year.~Exclusion Criteria:~* Subjects who are acutely ill, medically complicated or who are medically unstable as determined by the investigator.~* Suffering from COPD exacerbation at time of enrollment or 60 days prior~* Subjects who are not currently prescribed oxygen and manifest oxygen desaturation below 88% on the screening 6MWT~* Subjects with heart disease or neuromuscular disease.~* Subjects who are not prescribed short-acting bronchodilator medication~* Patients who have experienced recent barotrauma or pneumothorax~* Unstable angina or Myocardial Infarction during past month~* Uncontrolled Hypertension (systolic blood pressure of \>180mmHg (millimeters of Mercury) and a diastolic \>100mmHg)~* Heart Rate \>120 at rest~* Subjects who have trouble coordinating their breathing with the device during the device training, or cannot tolerate the device mouthpiece resulting in leaks from the nasal cavity~* Women of child-bearing potential (WOCP) who are pregnant, breast-feeding, or planning pregnancy during the course of the study. (WOCP must have a negative pregnancy test at every visit)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitabreath Device (Type: EXPERIMENTAL): The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
- Pursed Lip Breathing (Type: ACTIVE_COMPARATOR): Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets the following conditions:~  * A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)~ * Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis~ * Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kilopascal (kPa) OR~ * A historical liver biopsy within 12 months of screening consistent with NASH with fibrosis, but not cirrhosis, and~ * No documented weight loss \> 5% between the date of the liver biopsy and screening.~* Platelet count ≥ 150,000/mm\^3~* Albumin ≥ 3.3 g/dL~* Serum creatinine ≤ upper limit of normal (ULN)~Key Exclusion Criteria:~* Pregnant or lactating females~* Alanine aminotransferase (ALT) \> 5x upper limit of the normal range (ULN)~* Other causes of liver disease including autoimmune, viral, and alcoholic liver disease~* Cirrhosis of the liver~  * Prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding~* Body mass index (BMI) \< 18 kg/m\^2~* Uncontrolled diabetes mellitus (hemoglobin A1c \> 9% at screening)~* International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy~* Total bilirubin \> 1 x ULN, except with diagnosis of Gilbert's syndrome~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GS-9674 30 mg (Type: EXPERIMENTAL): GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
- GS-9674 100 mg (Type: EXPERIMENTAL): GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:~   \* 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound.~   OR~   \*If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.~2. Randomized within 24 hours of hospitalization for AHF~3. Planned use of IV loop diuretic therapy during current hospitalization~4. Estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73m2 by the MDRD equation~5. For diabetic patients, history of type 2 diabetes or a new hemoglobin A1c 6.5% on admission.~Exclusion Criteria:~1. Type 1 diabetes mellitus.~2. Dyspnea primarily due to non-cardiac causes.~3. Cardiogenic shock.~4. Acute coronary syndrome within 30 days prior to randomization.~5. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.~6. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH\>7.30 and glucose \>15 mmol/L and HCO3\>18 mmol/L).~7. Pregnant or nursing (lactating) women.~8. Heart failure due to drug toxicity~9. Adherence to medication less than 95%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozine 10mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, smoker (no more than 25 cigarettes daily) or non-smoker, 18 years of age and older, with BMI \> 18 and \< 30.0.~2. Females of childbearing potential who are sexually active must be willing to use two forms of contraceptive methods throughout the study and for 14days after the last study drug administration.~3. Minimum weight of 50 kg.~4. Good health, defined as not having history of any chronic illness and not requiring any regular medication/therapy.~5. Must swallow tablets on a regular basis.~Exclusion Criteria:~1. Evidence of Helicobacter pylori infection, presently, or within the last year.~2. Subjects with known hypersensitivity to cysteamine.~3. History, currently or within the past 3 months, of the following conditions:~   * Pancreatitis~  * Inflammatory bowel disease~  * Malabsorption~  * Severe liver disease~  * Unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias.~  * Unstable diabetes mellitus~  * Any bleeding disorder.~  * Zollinger-Ellison syndrome~  * Malignant disease~4. Subjects whom may be pregnant or have health issues that make it unsafe for them participate, or whose concomitant medical problems preclude them from committing to the study schedule.~5. Use of an investigational drug within 30 days (or 90 days for biologics) prior to dosing.~6. Use of prescription medication within 14 days prior to the first dosing;~7. Use over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to the first dosing.~8. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.~9. Hemoglobin \<13.5 g/dL (males) and \<12.0 g/dL (females) and hematocrit \<41.0% (males) and \<36.0% (females) at screening.~10. Breast-feeding subject.~11. Immunization with a live attenuated vaccine 1 month prior to dosing or planned vaccination during the course of the study.~12. Presence of fever (body temperature \>37.6°C) (e.g. a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cysteamine bitartrate (Type: EXPERIMENTAL): Cysteamine bitartrate, 500mg once a day, three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete